Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

Next Previous
Trial Profile

An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satricabtagene autoleucel (Primary) ; Cyclophosphamide; Docetaxel; Fludarabine; Irinotecan; Nivolumab; Paclitaxel; Rivoceranib
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors CARsgen

Most Recent Events

  • 22 Jun 2026 According to a CARsgen media release, company announced National Medical Products Administration approved New Drug Application (NDA) and launched satricabtagene autoleucel for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy.
  • 25 Jun 2025 According to a CARsgen media release, based on data from this trial the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy.
  • 01 Jun 2025 According to a CARsgen media release, company announces that the results of the pivotal Phase II clinical trial in China have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top